1. Home
  2. CGTX vs LODE Comparison

CGTX vs LODE Comparison

Compare CGTX & LODE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGTX
  • LODE
  • Stock Information
  • Founded
  • CGTX 2007
  • LODE 2008
  • Country
  • CGTX United States
  • LODE United States
  • Employees
  • CGTX 25
  • LODE N/A
  • Industry
  • CGTX Biotechnology: Pharmaceutical Preparations
  • LODE Major Chemicals
  • Sector
  • CGTX Health Care
  • LODE Industrials
  • Exchange
  • CGTX Nasdaq
  • LODE Nasdaq
  • Market Cap
  • CGTX 53.4M
  • LODE 53.0M
  • IPO Year
  • CGTX 2021
  • LODE N/A
  • Fundamental
  • Price
  • CGTX $0.84
  • LODE $3.66
  • Analyst Decision
  • CGTX Strong Buy
  • LODE Buy
  • Analyst Count
  • CGTX 4
  • LODE 1
  • Target Price
  • CGTX $2.83
  • LODE $26.00
  • AVG Volume (30 Days)
  • CGTX 19.4M
  • LODE 406.9K
  • Earning Date
  • CGTX 08-07-2025
  • LODE 08-07-2025
  • Dividend Yield
  • CGTX N/A
  • LODE N/A
  • EPS Growth
  • CGTX N/A
  • LODE N/A
  • EPS
  • CGTX N/A
  • LODE N/A
  • Revenue
  • CGTX N/A
  • LODE $3,376,027.00
  • Revenue This Year
  • CGTX N/A
  • LODE $33.58
  • Revenue Next Year
  • CGTX N/A
  • LODE N/A
  • P/E Ratio
  • CGTX N/A
  • LODE N/A
  • Revenue Growth
  • CGTX N/A
  • LODE 102.20
  • 52 Week Low
  • CGTX $0.22
  • LODE $1.26
  • 52 Week High
  • CGTX $2.54
  • LODE $10.10
  • Technical
  • Relative Strength Index (RSI)
  • CGTX 72.32
  • LODE 52.13
  • Support Level
  • CGTX $0.55
  • LODE $3.29
  • Resistance Level
  • CGTX $0.87
  • LODE $3.95
  • Average True Range (ATR)
  • CGTX 0.10
  • LODE 0.22
  • MACD
  • CGTX 0.02
  • LODE -0.01
  • Stochastic Oscillator
  • CGTX 61.76
  • LODE 56.06

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

About LODE Comstock Inc.

Comstock Inc innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock's innovations group is engaged in developing and using artificial intelligence technologies for advanced materials development.

Share on Social Networks: